Literature DB >> 30061230

Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer.

Katsuhiko Shimizu1, Riki Okita2, Shinsuke Saisho2, A I Maeda2, Yuji Nojima2, Masao Nakata2.   

Abstract

BACKGROUND/AIM: There is no clear evidence in the literature regarding the regulation of programmed cell death-ligand 1 (PD-L1) expression by cyclo-oxygenase-2 (COX2). In this study, whether PD-L1 expression was regulated by COX2 activity was examined in vitro.
MATERIALS AND METHODS: Resected lung cancer specimens were analyzed for PD-L1 and COX2 expression by immunohistochemical analysis. Next, co-localization of PD-L1 and COX2 expression was analyzed by double-fluorescence staining. Lastly, the effect of COX2 inhibition on the expression of PD-L1 was examined using lung cancer cell lines.
RESULTS: PD-L1 expression was significantly correlated with COX2 expression in the resected specimens. The majority of cancer cells that expressed PD-L1 also co-expressed COX2. However, treatment of lung cancer cell lines with a COX2 inhibitor had no impact on PD-L1 expression.
CONCLUSION: Our results suggest that COX2 inhibition might have no effect on the usage of immune checkpoint inhibitors in lung cancer treatment. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  COX2; COX2 inhibitor; Non-small cell lung cancer (NSCLC); PD-L1; co-localization

Mesh:

Substances:

Year:  2018        PMID: 30061230     DOI: 10.21873/anticanres.12768

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

Review 1.  Small molecular drugs reshape tumor microenvironment to synergize with immunotherapy.

Authors:  Chuanhui Han; Anli Zhang; Zhida Liu; Casey Moore; Yang-Xin Fu
Journal:  Oncogene       Date:  2020-12-07       Impact factor: 9.867

2.  COX-2 Inhibitors Decrease Expression of PD-L1 in Colon Tumors and Increase the Influx of Type I Tumor-infiltrating Lymphocytes.

Authors:  Denise L Cecil; Ekram A Gad; Lauren R Corulli; Nicholas Drovetto; Ronald A Lubet; Mary L Disis
Journal:  Cancer Prev Res (Phila)       Date:  2022-04-01

3.  Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.

Authors:  Federico Nichetti; Francesca Ligorio; Emma Zattarin; Diego Signorelli; Arsela Prelaj; Claudia Proto; Giulia Galli; Antonio Marra; Giulia Apollonio; Luca Porcu; Filippo de Braud; Giuseppe Lo Russo; Roberto Ferrara; Marina Chiara Garassino
Journal:  Cancers (Basel)       Date:  2019-12-25       Impact factor: 6.639

4.  PD-1 Blockade During Post-partum Involution Reactivates the Anti-tumor Response and Reduces Lymphatic Vessel Density.

Authors:  Beth A Jirón Tamburini; Alan M Elder; Jeffrey M Finlon; Andrew B Winter; Veronica M Wessells; Virginia F Borges; Traci R Lyons
Journal:  Front Immunol       Date:  2019-06-11       Impact factor: 7.561

5.  The PD-L1 metabolic interactome intersects with choline metabolism and inflammation.

Authors:  Jesus Pacheco-Torres; Marie-France Penet; Yelena Mironchik; Balaji Krishnamachary; Zaver M Bhujwalla
Journal:  Cancer Metab       Date:  2021-02-19

6.  Tofacitinib overcomes an IFNγ-induced decrease in NK cell-mediated cytotoxicity via the regulation of immune-related molecules in LC-2/ad.

Authors:  Riki Okita; Katsuhiko Shimizu; Yuji Nojima; Shinsuke Saisho; Masao Nakata
Journal:  Thorac Cancer       Date:  2021-01-24       Impact factor: 3.500

7.  Effect of cyclooxygenase inhibitor use on immunotherapy efficacy in non-small cell lung cancer.

Authors:  Osamu Kanai; Takanori Ito; Zentaro Saito; Yuki Yamamoto; Kohei Fujita; Misato Okamura; Masayuki Hashimoto; Koichi Nakatani; Satoru Sawai; Tadashi Mio
Journal:  Thorac Cancer       Date:  2021-02-09       Impact factor: 3.500

Review 8.  Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer.

Authors:  Dan Pu; Liyuan Yin; Lin Huang; Changlong Qin; Yuwen Zhou; Qiang Wu; Yan Li; Qinghua Zhou; Lu Li
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

Review 9.  The Inflammatory Profile of the Tumor Microenvironment, Orchestrated by Cyclooxygenase-2, Promotes Epithelial-Mesenchymal Transition.

Authors:  Fernán Gómez-Valenzuela; Enrico Escobar; Ricardo Pérez-Tomás; Viviana P Montecinos
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244

10.  Harnessing stemness and PD-L1 expression by AT-rich interaction domain-containing protein 3B in colorectal cancer.

Authors:  Tsai-Tsen Liao; Chun-Chi Lin; Jeng-Kae Jiang; Shung-Haur Yang; Hao-Wei Teng; Muh-Hwa Yang
Journal:  Theranostics       Date:  2020-05-15       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.